drugset / Trial / NCT00138632
Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
RandomizedParallel-groupTriple-blindTreatment
Summary
This study evaluates the tolerability and safety of 3 months treatment with PTK787 tablets given daily. It also explores the efficacy of the compound in patients with wet age-related macular edema. In Cohort 1 verteporfin/PDT is the active control. The protocol was amended to reflect the current standard of care for AMD. As a result, ranibizumab is the active control for Cohort 2.
Timeline
- Start
- 2005-09
- Primary completion
- 2007-11
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | vatalanib | Small molecule | 500 mg | Oral |
| Subject | vatalanib | Small molecule | 1000 mg | Oral |
| Background | Verteporfin | Other / unclassified | — | — |